Naomi Galili

10.8k citations

121 papers · 8.1k indexed · 5 hit papers · h-index 37

Hematology top 0.1%
- Acute Myeloid Leukemia Research 61
- Chronic Myeloid Leukemia Treatments 16
- Multiple Myeloma Research and Treatments 10
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 18
- Myeloproliferative Neoplasms: Diagnosis and Treatment 17
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment 15
Molecular Biology top 1%
Immunology top 2%
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 12
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 10

Co-authors: Azra Raza Michael L. Cleary G Rovera Frederic G. Barr Benjamin L. Ebert Beverly S. Emanuel Jamison L. Nourse Jeffrey Sklar
Cited by: Hematology Genetics Pathology and Forensic Medicine
Partner nations: United States Israel Sweden

In The Last Decade

Naomi Galili

119 papers receiving 7.9k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2014 Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
2011 Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2008 Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
1993 Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma
1990 Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor

Peers

Countries citing papers authored by Naomi Galili

Since Specialization

Citations

This map shows the geographic impact of Naomi Galili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naomi Galili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naomi Galili more than expected).

Fields of papers citing papers by Naomi Galili

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naomi Galili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naomi Galili. The network helps show where Naomi Galili may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Naomi Galili, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Naomi Galili Line = papers co-authored together Naomi Galili links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes Rafael Bejar,Kristen E. Stevenson,Bennett Adam Caughey,Omar Abdel‐Wahab,David P. Steensma,Naomi Galili,Azra Raza,Hagop M. Kantarjian,Ross L. Levine,Donna Neuberg,Guillermo Garcia‐Manero,Benjamin L. Ebert	2012	312
2	The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes Rong Wang,Cary P. Gross,Kevin D. Frick,Xiao Xu,Jessica B. Long,Azra Raza,Naomi Galili,Jennifer Zikria,Yongtao Guan,Xiaomei Ma	2012	23
3	Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes Xiaomei Ma,Rong Wang,Naomi Galili,Susan T. Mayne,Sa A. Wang,Herbert Yu,Azra Raza	2011	7
4	Pharmacotherapy of myelodysplastic syndromes Naomi Galili,Azra Raza	2010	2
5	Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features S. A. Wang,Kausar J. Jabbar,Gary Lu,S S Chen,Naomi Galili,Francisco Vega,Daniel M. Jones,Azra Raza,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Thérèse McDonnell,L. Jeffrey Medeiros	2010	12
6	An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome Benjamin L. Ebert,Naomi Galili,Pablo Tamayo,Jocelyn Bosco,Raymond H. Mak,Jennifer Pretz,Shyam Tanguturi,Christine Ladd‐Acosta,Richard M. Stone,Todd R. Golub,Azra Raza	2008	111
7	Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia Azra Raza,Murtaza Mehdi,Muhammad Ali Mumtaz,Fahad Ali,Steven Lascher,Naomi Galili	2008	54
8	Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBFβ-SMMHC in Acute Myelogenous Leukemia with inv(16) Ján Markus,Matthew T. Garin,Juraj Bies,Naomi Galili,Azra Raza,Michael J. Thirman,Michelle M. Le Beau,Janet D. Rowley,P. Paul Liu,Linda Wolff	2007	17
9	Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia Naomi Galili,Jan Černý,Azra Raza	2007	16
10	Low incidence of JAK2 and FLT3 mutations in patients with chronic myelomonocytic leukemia (CMML) Eric V. Sechman,Jan Černý,Murtaza Mehdi,Mohammad Mumtaz,Jessica Maguire,Peter Westervelt,Naomi Galili,Azra Raza	2006	1
11	Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease Sa A. Wang,Naomi Galili,Jan Černý,Eric V. Sechman,Su Sin Chen,Jerome Loew,Qin Liu,F S. Oluwole,Robert P. Hasserjian,Dan Jones,Huma Qawi,Bruce A. Woda,Azra Raza	2006	22
12	Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease Sa A. Wang,Naomi Galili,Jan Černý,Eric V. Sechman,Su Sin Chen,Jerome Loew,Qin Liu,F S. Oluwole,Robert P. Hasserjian,Dan Jones,Huma Qawi,Bruce A. Woda,Azra Raza	2006	21
13	Targeted therapies in myelodysplastic syndromes: ASH 2003 review Anna Candoni,Federico Silvestri,Silvia Buonamici,Donglan Li,P Manaswini Reddy,Naomi Galili,Giuseppina Nucifora,Azra Raza	2004	10
14	Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients Vilasini Shetty,Seema Hussaini,Sairah Alvi,Leena Joshi,Ahmed Shaher,Bruce Dangerfield,Fabiana Nascimben,Suneel Mundle,Krishnan Allampallam,Poluru L. Reddy,Naomi Galili,Azra Raza	2002	20
15	Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes Sairah Alvi,Ahmed Shaher,Vilasini Shetty,Benita Henderson,Bruce Dangerfield,Francesca Zorat,Leena Joshi,Shalini Anthwal,Laurie Lisak,Leslie Little,Sefer Gezer,Suneel Mundle,Poluru L. Reddy,Krishnan Allampallam,Xiaoke Huang,Naomi Galili,Raphael Borok,Azra Raza	2001	24
16	Structural and Mutational Analysis of a Conserved Gene (DGSI) from the Minimal DiGeorge Syndrome Critical Region Wànkuí Gǒng,Beverly S. Emanuel,Naomi Galili,David H. Kim,B.A. Roe,Deborah A. Driscoll,Marcia L. Budarf	1997	36
17	The pattern of joining (JH) gene usage in the human IgH chain is established predominantly at the B precursor cell stage Robert Wasserman,Yoshiaki Ito,Naomi Galili,M. Yamada,B A Reichard,S Shane,Beverly J. Lange,G Rovera	1992	28
18	Predominance of fetal type DJH joining in young children with B precursor lymphoblastic leukemia as evidence for an in utero transforming event. Robert Wasserman,Naomi Galili,Yoshiaki Ito,B A Reichard,S Shane,G Rovera	1992	65
19	Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factorbreakdown → Jamison L. Nourse,Julia D. Mellentin,Naomi Galili,Joyce Wilkinson,Eric J. Stanbridge,Stephen D. Smith,Michael L. Cleary	1990	581
20	Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. Michael L. Cleary,Naomi Galili,Jeffrey Sklar	1986	299

About Naomi Galili

Naomi Galili is a scholar working on Hematology, Genetics and Immunology, having authored 121 papers that have together received 8.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (61 papers), Chronic Lymphocytic Leukemia Research (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (16 papers), Lymphoma Diagnosis and Treatment (15 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), Multiple Myeloma Research and Treatments (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). The work is most often cited by research in Hematology (3.6k citations), Genetics (1.8k citations) and Pathology and Forensic Medicine (1.1k citations). Naomi Galili has collaborated with scholars based in United States, Israel and Sweden. Frequent co-authors include Azra Raza, Michael L. Cleary, G Rovera, Frederic G. Barr, Benjamin L. Ebert, Beverly S. Emanuel, Jamison L. Nourse, Jeffrey Sklar, William J. Fredericks and Frank J. Rauscher.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact